Avanir Pharma says higher dose of Zenvia reduced number of emotional outbursts tied to disease

Avanir posts mixed late stage Zenvia study results

ALISO VIEJO, Calif. — Avanir Pharmaceuticals Inc. on Friday reported mixed results for its drug candidate Zenvia, which is intended to reduce involuntary emotional outbursts in patients with neurological disorders.

Shares of Acorda Therapeutics dive after FDA questions experimental multiple sclerosis drug

Acorda shares plunge on negative FDA review

WASHINGTON — Shares of Acorda Therapeutics plummeted Friday after the Food and Drug Administration issued a negative opinion that questioned the safety and effectiveness of the company’s multiple sclerosis drug.

Report finds Alzheimer’s, dementia afflict more than 35 million worldwide and rising rapidly

Report: 35 million-plus worldwide have dementia

WASHINGTON — More than 35 million people around the world are living with Alzheimer’s disease or other types of dementia, says the most in-depth attempt yet to assess the brain-destroying illness — and it’s an ominous forecast as the population grays.

Acadia Pharmaceuticals shares plunge as Parkinson’s disease drug fails late-stage study

Acadia shares fall on failed Parkinson’s study

NEW YORK — Shares of Acadia Pharmaceuticals Inc. plunged Tuesday after the company said its drug candidate pimavanserin failed to meet key treatment goals in a late-stage study focusing on patients with Parkinson’s disease psychosis.

HEALTHBEAT: Amid flu flurry, don’t forget teen shots against different threat _ meningitis

Rare but deadly meningitis: Don’t forget kid shots

WASHINGTON — Fever, chills, vomiting: It starts like a stomach bug or the flu. But bacterial meningitis can go on to kill terrifyingly fast — one of the few infections in the U.S. where someone can feel fine in the morning and be dead by night. And prime targets are tweens, teens and college freshmen.